US impacted by high base; regulatory actions in India; currency volatility in EM: Although US base business (ex Nexium and Invagen) grew >30% YoY, overall US sales declined 26% YoY to USD98m. CIPLA expects the US portfolio to deliver robust growth on the back of its strong launch pipeline (~15 launches expected in rest of FY17) and enhanced focus on R&D.; Domestic formulation sales grew 5% YoY in 1QFY17 (~2% impact due to regulatory issues). According to IMS, secondary sales grew ~13% in 1Q. South Africa business grew 22% YoY in constant currency, but...